Atai Life Sciences N.V. completed its acquisition of Beckley Psytech Limited on 2025-11-05, according to the Form 8-K Atai Life Sciences N.V. filed with the SEC on 2025-11-05. The filing's Item 2.01 states no aggregate dollar price.
| Acquirer | Atai Life Sciences N.V. |
|---|---|
| Acquired | Beckley Psytech Limited |
| Completed | 2025-11-05 |
| Reported by | Atai Life Sciences N.V. (ATAI), the buyer |
| Filing | Form 8-K, filed 2025-11-05 |
Want the whole picture on Atai Life Sciences N.V.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Atai Life Sciences N.V.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Atai Life Sciences N.V. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
1 cited source found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
What the filing says
In connection with the Acquisition, the Company acquired all of the issued and outstanding equity interests of Beckley Psytech in exchange for an aggregate of 103,000,066 ordinary shares in atai's capital ("Ordinary Shares") issued directly as share consideration or as underlying replacement awards pursuant to the Purchase Agreement, which such shares or replacement awards were issued to the shareholders of Beckley Psytech, certain consultants of Beckley Psytech and certain equity award holders in Beckley Psytech.
More from the filing
On November 5, 2025, Atai Beckley N.V. (f/k/a ATAI Life Sciences N.V.) ("atai" or the "Company") completed its previously announced acquisition of the entire issued share capital of Beckley Psytech Limited ("Beckley Psytech") not already owned by the Company (the "Acquisition") from the shareholders of Beckley Psytech, pursuant to that certain Share Purchase Agreement, dated as of June 2, 2025, by and among the parties thereto, as amended (the "Purchase Agreement").
Quoted from Atai Life Sciences N.V.'s Form 8-K.
This is the only completed acquisition Atai Life Sciences N.V. reported under Item 2.01 in the last twelve months.
Who runs it now, who owns it, where the money comes from and what to watch for, every claim linked to its source.
Order Full Report on Atai Life Sciences N.V.Look up Atai Life Sciences N.V. and see what is on record before you decide.
Get the free SnapshotWhere this comes from
A public company must file a current report on Form 8-K with the SEC within four business days of completing a significant acquisition or disposition of assets, under Item 2.01 of the report. The acquired company sometimes files one too, when the deal makes it a subsidiary of the buyer.
Every fact on this page is taken from one of those filings and linked to it: which company acquired which, the date the filing gives for completion, and the price when the filing states one in dollars, shown next to the sentence that states it. A filing states what was bought and on what terms; it rarely states why, and neither does this page.